Vol. 37. No. 1
One theme that runs through many of the articles is the advent of targeted therapies. As the community has gained a greater comprehension of the pathogenesis behind many of these diseases, the development of these targeted therapies has become possible.MORE
Conventional systemic chemotherapy and single-agent chemotherapy (eg, gemcitabine) give usually good results in advanced MF, but recurrences are the rule. Monoclonal antibodies directed against cluster of differentiation (CD)52 (alemtuzumab), CD30 (brentuximab vedotin), and chemokine receptor 4 (CCR4; mogamulizumab), as well as several other experimental therapies, have shown promising results and represent a valid alternative.MORE
In this review, the clinical and histopathologic features, differential diagnosis, and treatment of these 3 variants are presented. Hypopigmented MF, which is the most common variant in childhood and adolescence, and other rare variants are shortly discussed.MORE
Since the first patients were described in the mid-20th century, criteria to define SS have been debated. Many authorities agree that SS is defined by the presence of erythroderma and blood involvement by malignant lymphocytes that has not been preceded by typical lesions of mycosis fungoides; lymphadenopathy is also a common finding.MORE
Cutaneous CD30-positive T-cell lymphoproliferative disorders— clinical and histopathologic features, differential diagnosis, and treatment
This review describes the clinicopathologic features of CD30+ LPDs, their differential diagnoses, the treatment, and the role ofCD30 as a diagnostic marker and therapeutic target.